Gland Pharma Issues €20 Mn Corporate Guarantee for Subsidiary Phixen SAS
Gland Pharma Ltd · Others (Uncategorized) · 12 Nov 2026, 10:49 pm
Gland Pharma Issues €20 Mn Corporate Guarantee for Subsidiary Phixen SAS Gland Pharma Limited has issued a corporate guarantee of €20 Mn in favor of MUFG Bank (Europe) N.V. on behalf of its wholly owned step-down subsidiary, Phixen SAS. The guarantee secures an uncommitted revolving facility of €50 Mn (initial drawdown limit of €18 Mn) entered by Phixen SAS. The facility agreement is valid for three years, while the corporate guarantee remains valid until 31st Mar'30 and will be treated as a contingent liability for Gland Pharma. The guarantee limit may expand if future drawdown limits increase.
Original exchange filing (PDF)
More announcements from Gland Pharma Ltd
- Schedule of Investor Meet Intimation · 17 Nov 2026
- Allotment of 3739 Equity Shares on exercise of ESOPs · 16 Nov 2026
- Grant of Options to Purchase Securities · 16 Nov 2026
- Q2FY27 Earnings Call Transcript · 12 Nov 2026
- Appointment of Mr. Xiao Le as Chief Investment Officer at Gland Pharma International Pte. Ltd, wholly owned subsidiary of Gland Pharma Limited, effective November 09, 2026 · 09 Nov 2026
- Q2FY27 Earnings Call Recording · 07 Nov 2026
- Q2Fy27 Investors presentation · 06 Nov 2026
- Unaudited Financial Results for the Quarter and half year ended September 30, 2026 · 06 Nov 2026
